Table 1 Baseline characteristics
Switching therapy group | Add-on therapy group | |
|---|---|---|
n = 6 | n = 4 | |
Age (years) | 72 ± 13 | 68 ± 14 |
Sex (male:female) | 3 (50):3 (50) | 0 (0):4 (100) |
Type of surgerya | ||
Intraperitoneal | 2 | 1 |
Orthopedic | 2 | 1 |
Peripheral Vascular | – | 1 |
Lung | 1 | – |
Urological | 1 | – |
Thyroid | – | 1 |
Surgical riskb | ||
High | 1 (17) | 1 (25) |
Intermediate | 5 (83) | 1 (25) |
Low | 0 (0) | 2 (50) |
Oral β-blocker | ||
Bisoprolol (7.5 mg) | 1 (17) | – |
Bisoprolol (5 mg) | 5 (83) | – |
None | – | 4 (100) |
Bisoprolol transdermal patch | ||
8 mg | 6 (100) | 1 (25) |
4 mg | 0 (0) | 3 (75) |
Class IA agentsc | 5 (83) | 4 (100) |
Class III agents | 0 (0) | 0 (0) |
Calcium-channel blockers | 5 (83) | 1 (25) |
Diuretics | 1 (17) | 0 (0) |
Height (cm) | 156 ± 11 | 155 ± 5 |
Weight (kg) | 59 ± 15 | 57 ± 10 |
BMI (kg/m2) | 24 ± 4 | 24 ± 3 |
NYHA class | ||
I | 2 (33) | 1 (25) |
IIs | 2 (33) | 3 (75) |
IIm | 1 (17) | 0 (0) |
III | 1 (17) | 0 (0) |
IV | 0 (0) | 0 (0) |
Type of obstruction | ||
LVOTO | 5 (83) | 3 (75) |
MVO | 1 (17) | 1 (25) |
Prior PTSMA | 4 (67) | 0 (0) |
FH-SCD | 1 (17) | 0 (0) |
VT/Vf | 0 (0) | 0 (0) |
Af | 3 (50) | 0 (1) |
Prior pacemaker/ICD | 1 (17) | 0 (2) |
Measurements of the left ventricle | ||
IVST (mm) | 15 ± 1 | 15 ± 5 |
PWT (mm) | 12 ± 2 | 12 ± 2 |
LAD (mm) | 42 ± 8 | 37 ± 2 |
LVDd (mm) | 44 ± 8 | 40 ± 2 |
LVDs (mm) | 28 ± 9 | 22 ± 1 |